Editas Medicine Unveils In Vivo Gene Editing Data

Editas Medicine ( (EDIT) ) has shared an announcement.

On May 13, 2025, Editas Medicine announced in vivo proof of concept data for a liver target at the American Society of Gene and Cell Therapy Annual Meeting. The study demonstrated significant gene editing and protein upregulation in mice and monkeys, indicating potential for a first-in-class treatment for liver diseases. This advancement positions Editas as a leader in gene editing therapies, with plans to reveal more details about the target and development candidate later in the year.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Spark’s Take on EDIT Stock

According to Spark, TipRanks’ AI Analyst, EDIT is a Underperform.

Editas Medicine’s overall stock score reflects significant financial challenges and speculative valuation. The company’s financial performance indicates difficulties in achieving profitability, with consistent negative cash flows and no current revenue. While technical indicators suggest short-term stability, the long-term downtrend remains a concern. The speculative nature of its valuation further underscores the high-risk profile of the stock, making it suitable primarily for risk-tolerant investors.

To see Spark’s full report on EDIT stock, click here.

More about Editas Medicine

Editas Medicine is a pioneering gene editing company focused on harnessing the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems to develop in vivo medicines for serious diseases globally. The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines and holds exclusive licenses for Cas12a and Cas9 patent estates for human medicines.

Average Trading Volume: 3,827,929

Technical Sentiment Signal: Sell

Current Market Cap: $128.9M

Learn more about EDIT stock on TipRanks’ Stock Analysis page.